GHK-CuvsGonadorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
01Mechanism of Action
02Dosage Protocols
03Metabolic / Fat Loss Evidence
04Side Effects & Safety
- ·Wilson disease (copper-overload disorder)
- ·Pregnancy / breastfeeding
- ·Known copper hypersensitivity
- ·Pregnancy (except therapeutic infertility protocols)
- ·Hypersensitivity to gonadorelin or excipients
- ·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation
- ·Hemochromatosis (copper-iron crosstalk theoretical)
- ·Concurrent copper-chelator therapy
- ·Ovarian cysts or PCOS (monitor for OHSS)
- ·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)
05Administration Protocol
06Stack Synergy
GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.
- GHK-Cu
- 1–2 mg SQ · daily near wound
- BPC-157
- 250–500 mcg SQ · daily near wound
- Primary benefit
- Combined ECM rebuilding + angiogenesis for tissue repair
In hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.
- Gonadorelin
- 5–10 mcg IV every 120 min (pulsatile pump)
- hCG
- 1500–2000 IU SQ · 2–3× per week
- Duration
- 12–24 weeks for spermatogenesis induction
- Primary benefit
- Fertility restoration in hypothalamic hypogonadism with maintained testicular function